See more : Global Boatworks Holdings, Inc. (GBBT) Income Statement Analysis – Financial Results
Complete financial analysis of Spyre Therapeutics, Inc. (SYRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spyre Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Man Wah Holdings Limited (MAWHY) Income Statement Analysis – Financial Results
- Orphazyme A/S (ORPHA.CO) Income Statement Analysis – Financial Results
- PC Connection, Inc. (CNXN) Income Statement Analysis – Financial Results
- Nippon Paper Industries Co., Ltd. (NIJPF) Income Statement Analysis – Financial Results
- Daesang Corporation (001685.KS) Income Statement Analysis – Financial Results
Spyre Therapeutics, Inc. (SYRE)
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 886.00K | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 0.00 | 0.00 | 0.00 | 89.00K | 19.00K |
| Gross Profit | -78.00K | 365.00K | 16.74M | -1.62M | -901.00K | 3.89M | 5.21M | 4.63M | 6.00M | -19.00K |
| Gross Profit Ratio | -8.80% | 15.67% | 89.32% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 98.54% | 0.00% |
| Research & Development | 89.50M | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 39.95M | 28.53M | 27.32M | 21.84M | 0.00 | 0.00 | 0.00 | 0.00 | 5.95M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 39.95M | 28.53M | 27.32M | 21.84M | 14.83M | 12.34M | 9.82M | 8.26M | 5.95M | 2.06M |
| Other Expenses | 113.74M | -7.00K | -122.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 79.43M | 49.06M | 32.63M | 26.40M | 17.40M | 8.89M |
| Cost & Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 6.15M | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -127.82M | -83.21M | -63.66M | -79.27M | -77.35M | -45.17M | -27.43M | -21.77M | -11.23M | -10.33M |
| EBITDA Ratio | -14,426.64% | -3,572.95% | -341.92% | 0.00% | 0.00% | -1,161.78% | -526.94% | -470.48% | -184.49% | 0.00% |
| Operating Income | -242.30M | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -27,347.97% | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | -96.51M | 830.00K | -11.00K | 588.00K | 2.08M | 1.12M | 440.00K | 208.00K | 20.00K | -1.44M |
| Income Before Tax | -338.82M | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -38,241.08% | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -26.00K | -136.00K | 141.00K | -593.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -338.79M | -83.82M | -65.80M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -38,238.15% | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -25.20 | -18.91 |
| EPS Diluted | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -25.20 | -18.91 |
| Weighted Avg Shares Out | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
| Weighted Avg Shares Out (Dil) | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Spyre Therapeutics, Inc. ("Spyre" or "the Company") (NASDAQ:SYRE). Investors who purchased Spyre securities are encouraged to...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
WALTHAM, Mass. , Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
WALTHAM, Mass. , Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment...
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing
SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection Planned Phase 2 induction regimen...
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
WALTHAM, Mass. , Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the...
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the...
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
WALTHAM, Mass. , Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease...
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical activity including comparable potency and a greater than three-fold extension in half-life in...
Source: https://incomestatements.info
Category: Stock Reports